Search

Your search keyword '"Genestreti G"' showing total 119 results
Start Over Author "Genestreti G"
119 results on '"Genestreti G"'

2. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study

Author

Pilotto, S, Rossi, A, Vavalà, T, Follador, A, Tiseo, M, Galetta, D, Morabito, A, Di Maio, M, Martelli, O, Caffo, O, Piovano, P, Cortinovis, D, Zilembo, N, Casartelli, C, Banna, G, Ardizzoia, A, Barzelloni, M, Bearz, A, Genestreti, G, Mucciarini, C, Filipazzi, V, Menis, J, Rizzo, E, Barbieri, F, Rijavec, E, Cecere, F, Spitaleri, G, Bria, E, Novello, S, Pilotto S, Rossi A, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Spitaleri G, Bria E, Novello S., Pilotto, S, Rossi, A, Vavalà, T, Follador, A, Tiseo, M, Galetta, D, Morabito, A, Di Maio, M, Martelli, O, Caffo, O, Piovano, P, Cortinovis, D, Zilembo, N, Casartelli, C, Banna, G, Ardizzoia, A, Barzelloni, M, Bearz, A, Genestreti, G, Mucciarini, C, Filipazzi, V, Menis, J, Rizzo, E, Barbieri, F, Rijavec, E, Cecere, F, Spitaleri, G, Bria, E, Novello, S, Pilotto S, Rossi A, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Spitaleri G, Bria E, and Novello S.

Abstract

Non-small-cell lung cancer harboring uncommon epidermal growth factor receptor (EGFR) mutations (any mutation other than deletion 19 or substitution of leucine by arginine at codon 858) presents a variable sensitivity to EGFR-tyrosine kinase inhibitors. With the final aim to enrich knowledge about uncommon EGFR mutations, we performed a post hoc analysis of the beyond progression after tyrosine kinase inhibitor in EGFR-positive non-small-cell lung cancer patients (BE-POSITIVE) trial. Thirty-five patients were included of the original 312 EGFR-mutated cases. The results of our analysis support the existence of a strong heterogeneity within patients harboring uncommon EGFR mutations, which implies the necessity to stratify the subgroups of rare mutations in individual entities with different clinical perspectives. Background: Beyond progression after tyrosine kinase inhibitor in EGFR-positive non-small-cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study that reported the outcomes of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in a “real-life” Caucasian EGFR-mutated non-small-cell lung cancer (NSCLC) population. The sharing of multi-institutional experiences represents a crucial strategy to enrich knowledge about uncommon EGFR mutations. Therefore, we performed a post hoc analysis of the BE-POSITIVE study. Patients and Methods: Data of advanced NSCLC patients with uncommon EGFR mutations who received first-line first-generation EGFR-TKIs in 24 Italian Hospitals were collected. In this analysis we aimed to evaluate overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) of EGFR-TKIs in NSCLC patients harboring uncommon EGFR mutations. Results: Thirty-five patients harboring uncommon EGFR mutations (any mutation other than deletion 19 or substitution of leucine by arginine at codon 858) were included of the original 312 EGFR-mutated cases. Most of them

Published
2018

5. Small cell lung cancer

Author

Rosti, G., Bevilacqua, G., Bidoli, P., Portalone, L., Santo, A., and Genestreti, G.

Published
2006

9. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study

Author

Vavalà, T, Follador, A, Tiseo, M, Galetta, D, Morabito, A, Di Maio, M, Martelli, O, Caffo, O, Piovano, P, Cortinovis, D, Zilembo, N, Casartelli, C, Banna, G, Ardizzoia, A, Barzelloni, M, Bearz, A, Genestreti, G, Mucciarini, C, Filipazzi, V, Menis, J, Rizzo, E, Barbieri, F, Rijavec, E, Cecere, F, Bria, E, Spitaleri, G, Rossi, A, Novello, S, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Bria E, Spitaleri G, Rossi A, Novello S., Vavalà, T, Follador, A, Tiseo, M, Galetta, D, Morabito, A, Di Maio, M, Martelli, O, Caffo, O, Piovano, P, Cortinovis, D, Zilembo, N, Casartelli, C, Banna, G, Ardizzoia, A, Barzelloni, M, Bearz, A, Genestreti, G, Mucciarini, C, Filipazzi, V, Menis, J, Rizzo, E, Barbieri, F, Rijavec, E, Cecere, F, Bria, E, Spitaleri, G, Rossi, A, Novello, S, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Bria E, Spitaleri G, Rossi A, and Novello S.

Abstract

Objectives: Non-small-cell-lung-cancer (NSCLC) patients harbouring epidermal growth factor receptor (EGFR) mutations develop drug resistance after 9-12 months of EGFR tyrosine kinase inhibitors (TKIs) therapy pointing out the issue of the second-line treatment choice. Materials and methods: From June 2009 until May 2013 patients affected by advanced NSCLC harbouring EGFR mutations receiving first-line TKI were collected mainly retrospectively in 24 Italian Centers. Primary objective was to describe the percentage of EGFR mutated patients receiving second-line therapy after progression to first-line EGFR-TKIs assessing the type, the activity in terms of objective response rate (ORR), efficacy in terms of progression free survival (PFS) and overall survival (OS), and safety of second-line treatment. Secondary objective was to describe the efficacy of first-line EGFR-TKIs. Results: 312 patients were included. Most of them were females (203, 65.1%), never smokers (200, 64.1%), with adenocarcinoma histology (290, 92.9%). The most common mutations were EGFR exon 19 deletion and L858R, detected in 186 and 97 cases (59.6% and 31.1%), respectively. At data cut-off, 274 patients (95.1%) received any second-line treatment (including best supportive care or local treatments only). A total of 163 patients received second-line systemic therapy with an ORR of 20.9% (95% CI:14.62-27.10), a median PFS and OS of 4.7 (95% CI:3.81-5.26) and 24.5 (95% CI:21.65-27.37) months, respectively. Grade 3-4 hematological and non-hematological toxicities were reported in 9% and 6.3% of 144 patients treated with chemotherapy while non-hematological toxicity was reported in 4 cases of the 17 patients receiving second-line target agents. Conclusions: BE-Positive is the first multicenter observational study reporting outcomes of therapies in a "real-life Caucasian EGFR-mutated population", highlighting the need of further researches about new treatment strategies in this setting.

Published
2016

10. Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer

Author

Di Maio, M, Leighl, Nb, Gallo, C, Feld, R, Ciardiello, F, Butts, C, Maione, P, Gebbia, V, Morgillo, F, Wierzbicki, R, Favaretto, A, Alam, Y, Cinieri, S, Siena, S, Bianco, R, Riccardi, F, Spatafora, M, Ravaioli, A, Felletti, R, Fregoni, V, Genestreti, G, Rossi, A, Mancuso, G, Fasano, M, Morabito, A, Tsao, Ms, Signoriello, S, Perrone, F, Gridelli, C, Torch, Investigators, Calabro', L, Di Maio, M., Leighl, N. B., Gallo, C., Feld, R., Ciardiello, F., Butts, C., Maione, P., Gebbia, V., Morgillo, F., Wierzbicki, R., Favaretto, A., Alam, Y., Cinieri, S., Siena, S., Bianco, Roberto, Riccardi, F., Spatafora, M., Ravaioli, A., Felletti, R., Fregoni, V., Genestreti, G., Rossi, A., Mancuso, G., Fasano, M., Morabito, A., Tsao, M. S., Signoriello, S., Perrone, F., Gridelli, C., Di Maio, M, Leighl, N, Gallo, C, Feld, R, Ciardiello, F, Butts, C, Maione, P, Gebbia, V, Morgillo, F, Wierzbicki, R, Favaretto, A, Alam, Y, Cinieri, S, Siena, S, Bianco, R, Riccardi, F, Spatafora, M, Ravaioli, A, Felletti, R, Fregoni, V, Genestreti, G, Rossi, A, Mancuso, G, Fasano, M, Morabito, A, Tsao, M, Signoriello, S, Perrone, F, Gridelli, C, and Leighl, Nb

Subjects
Oncology, Male, erlotinib, Lung Neoplasms, Health-related quality of life, NSCLC, chemotherapy, Deoxycytidine, law.invention, Randomized controlled trial, Quality of life, law, Carcinoma, Non-Small-Cell Lung, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols, Surveys and Questionnaire, Quality of life analysis of TORCH, Erlotinib Hydrochloride, Prognosis, humanities, Research Design, Advanced non–small-cell lung cancer, Carcinoma, Squamous Cell, Female, Erlotinib, Randomized trial, medicine.drug, Human, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Prognosi, EGFR, First-line treatment, first-line erlotinib, second-line cisplatin/gemcitabine chemotherapy, Adenocarcinoma, NO, Follow-Up Studie, Internal medicine, advanced non-small-cell lung cancer, medicine, Humans, Lung cancer, Advanced non-small-cell lung cancer, Chemotherapy, Quality of life analysis of TORCH , first-line erlotinib , second-line cisplatin/gemcitabine chemotherapy, advanced non-small-cell lung cancer, Aged, Neoplasm Staging, Salvage Therapy, Antineoplastic Combined Chemotherapy Protocol, business.industry, Questionnaire, Cancer, Quinazoline, medicine.disease, Interim analysis, Gemcitabine, Surgery, Lung Neoplasm, quality of life, Quinazolines, Carcinoma, Large Cell, Cisplatin, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

INTRODUCTION:: The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. standard inverse sequence. The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm. Quality of life (QoL), a secondary outcome, is reported here. METHODS:: QoL was assessed at baseline and every 3 weeks during first-line, using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 and QLQ-lung cancer specific module (LC13). Mean changes from baseline within arms were reported. QoL response and time-to-deterioration of QoL using a competing-risk approach were compared between treatment arms. RESULTS:: Six hundred and thirty patients (83%) completed baseline questionnaires. Compliance was affected by differential treatment efficacy, but was similar between arms for patients without progression or death. Significant differences in QoL responses were observed favoring chemotherapy for pain, sleeping, dyspnea, diarrhea, and favoring erlotinib for vomiting, constipation, sore mouth, and alopecia. In the small subset of patients with EGFR-mutated tumors, all selected items (global QoL, physical functioning, cough, dyspnea and pain) improved, whereas worsening or no change was observed in wild-type patients. Improvement was particularly evident in the first-line erlotinib arm as for global QoL and physical functioning. CONCLUSIONS:: QoL was impacted by differential toxicity and efficacy between arms. Functional domains and global QoL did not differ, although some symptoms were better controlled with chemotherapy in unselected non-small-cell lung cancer patients. © 2012 by the International Association for the Study of Lung Cancer.

Published
2012

11. The role of clinical and molecular characteristics in low grade gliomas

Author

Mura, A., primary, Franceschi, E., additional, Minichillo, S., additional, Tosoni, A., additional, Fioravanti, A., additional, Talacchi, A., additional, Volpin, L., additional, Tallini, G., additional, De Biase, D., additional, Visani, M., additional, Degli Esposti, R., additional, Genestreti, G., additional, Pizzolitto, S., additional, Agati, R., additional, Bortolotti, C., additional, Bartolini, S., additional, Paccapelo, A., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

12. IDH mutant and 1p19q codeleted low grade gliomas: to treat or not to treat?

Author

Tosoni, A., primary, Franceschi, E., additional, Mura, A., additional, Minichillo, S., additional, Pession, A., additional, De Biase, D., additional, Danieli, D., additional, Pizzolitto, S., additional, Fioravanti, A., additional, Volpin, L., additional, Agati, R., additional, Genestreti, G., additional, Degli Esposti, R., additional, Bartolini, S., additional, Paccapelo, A., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

13. The role of treatments in IDH mutant molecular astrocytomas

Author

Minichillo, S., primary, Franceschi, E., additional, Mura, A., additional, Tosoni, A., additional, Tallini, G., additional, Pession, A., additional, Foschini, M., additional, Bortolotti, C., additional, Danieli, D., additional, Talacchi, A., additional, Cirillo, L., additional, Di Battista, M., additional, Genestreti, G., additional, Bartolini, S., additional, Paccapelo, A., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

14. Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

Author

Banna, G, Di Maio, M, Follador, A, Collovà, E, Menis, J, Novello, S, Bria, E, Airoldi, M, Amoroso, D, Ardizzoia, A, Aurilio, G, Bajetta, E, Ballardini, P, Barbieri, F, Barletta, E, Balzelloni, M, Basso, U, Bernardini, I, Boni, C, Bordin, V, Bretti, S, Bronte, G, Brunetti, C, Buti, S, Capanna, L, Colombo, A, Condemi, G, Cortinovis, D, Dambrosio, M, Di Fonzo, C, Di Lucca, G, Dima, G, Falzetta, A, Favaretto, A, Ferraù, F, Garetto, L, Gebbia, V, Genestreti, G, Gentile, A, Giovanardi, F, Labianca, R, Lorusso, V, Mantovani, G, Martelli, O, Massari, F, Mazzoli, M, Michetti, G, Mordenti, P, Mucciarini, C, Munao, S, Nacci, A, Pogliani, C, Procopio, G, Riccardi, F, Rizzato, S, Rossi, A, Rosti, G, Russo, P, Saladino, T, Salesi, N, Santangelo, D, Sava, T, Savarino, A, Spinnato, F, Tiseo, M, Tomassi, O, Tondulli, L, Tonini, G, Turano, S, Valerio, M, Verderame, F, Zanelli, F, Zanon, E, Banna GL, Di Maio M, Follador A, Collovà E, Menis J, Novello S, Bria E, Airoldi M, Amoroso D, Ardizzoia A, Aurilio G, Bajetta E, Ballardini P, Barbieri F, Barletta E, Balzelloni ML, Basso U, Bernardini I, Boni C, Bordin V, Bretti S, Bronte G, Brunetti C, Buti S, Capanna L, Colombo A, Condemi G, Cortinovis D, Dambrosio M, Di Fonzo C, Di Lucca G, Dima G, Falzetta A, Favaretto A, Ferraù F, Garetto L, Gebbia V, Genestreti G, Gentile AL, Giovanardi F, Labianca R, Lorusso V, Mantovani G, Martelli O, Massari F, Mazzoli M, Michetti G, Mordenti P, Mucciarini C, Munao S, Nacci A, Pogliani C, Procopio G, Riccardi F, Rizzato S, Rossi A, Rosti G, Russo P, Saladino T, Salesi N, Santangelo D, Sava T, Savarino A, Spinnato F, Tiseo M, Tomassi O, Tondulli L, Tonini G, Turano S, Valerio MR, Verderame F, Zanelli F, Zanon E., Banna, G, Di Maio, M, Follador, A, Collovà, E, Menis, J, Novello, S, Bria, E, Airoldi, M, Amoroso, D, Ardizzoia, A, Aurilio, G, Bajetta, E, Ballardini, P, Barbieri, F, Barletta, E, Balzelloni, M, Basso, U, Bernardini, I, Boni, C, Bordin, V, Bretti, S, Bronte, G, Brunetti, C, Buti, S, Capanna, L, Colombo, A, Condemi, G, Cortinovis, D, Dambrosio, M, Di Fonzo, C, Di Lucca, G, Dima, G, Falzetta, A, Favaretto, A, Ferraù, F, Garetto, L, Gebbia, V, Genestreti, G, Gentile, A, Giovanardi, F, Labianca, R, Lorusso, V, Mantovani, G, Martelli, O, Massari, F, Mazzoli, M, Michetti, G, Mordenti, P, Mucciarini, C, Munao, S, Nacci, A, Pogliani, C, Procopio, G, Riccardi, F, Rizzato, S, Rossi, A, Rosti, G, Russo, P, Saladino, T, Salesi, N, Santangelo, D, Sava, T, Savarino, A, Spinnato, F, Tiseo, M, Tomassi, O, Tondulli, L, Tonini, G, Turano, S, Valerio, M, Verderame, F, Zanelli, F, Zanon, E, Banna GL, Di Maio M, Follador A, Collovà E, Menis J, Novello S, Bria E, Airoldi M, Amoroso D, Ardizzoia A, Aurilio G, Bajetta E, Ballardini P, Barbieri F, Barletta E, Balzelloni ML, Basso U, Bernardini I, Boni C, Bordin V, Bretti S, Bronte G, Brunetti C, Buti S, Capanna L, Colombo A, Condemi G, Cortinovis D, Dambrosio M, Di Fonzo C, Di Lucca G, Dima G, Falzetta A, Favaretto A, Ferraù F, Garetto L, Gebbia V, Genestreti G, Gentile AL, Giovanardi F, Labianca R, Lorusso V, Mantovani G, Martelli O, Massari F, Mazzoli M, Michetti G, Mordenti P, Mucciarini C, Munao S, Nacci A, Pogliani C, Procopio G, Riccardi F, Rizzato S, Rossi A, Rosti G, Russo P, Saladino T, Salesi N, Santangelo D, Sava T, Savarino A, Spinnato F, Tiseo M, Tomassi O, Tondulli L, Tonini G, Turano S, Valerio MR, Verderame F, Zanelli F, and Zanon E.

Abstract

Background: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤1). Post-operative radiotherapy (RT) is optional for pN2 tumours. Patients and methods: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail. Results: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage IIA, IIB, IIIA, and IIIB disease, respectively and 14% in stage IB disease. Stage, PS, and age are taken into consideration evaluating adjuvant approach by 97, 95 and 73%, respectively. Cisplatin-vinorelbine (64%) and cisplatin-gemcitabine (33%), for 4 cycles (81%), are the preferred regimens, while 32% use different regimens. Ninety-two percent indicate RT in pN2 disease and/or positive resection margins. Real Number of patients Needed to Treat (NNT) is probably not completely known/understood and/or used by physicians. Conclusions: A substantial adherence between clinical daily practice in Italy and scientific progresses is described in this paper, even with some discordances regarding the most appropriate adjuvant chemotherapy regimen.

Published
2011

15. Small cell lung cancer

Author

Rosti, G, Bevilacqua, G, Bidoli, P, Portalone, L, Santo, A, Genestreti, G, Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo A, Genestreti G, Rosti, G, Bevilacqua, G, Bidoli, P, Portalone, L, Santo, A, Genestreti, G, Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo A, and Genestreti G

Abstract

Small cell lung cancer accounts for 13-15% of all lung cancer worldwide. There has been a decrease in the number of cases, with no clear explanation, except probably to changing in smoking habits in the last two decades. In the early eighties, it became clear that SCLC was an extremely sensitive tumor as to radiation as to chemotheraputic agents. With cisplatinum etoposide combinations or cyclophosphamide, anthracycline and vincristine/etyoposide regimens responses were observed in 50-70%, with 20-30% complete remissions in extensive disease. For limited stage patients chemotherapy associated with thoracic radiation was able to produce a cure rate of 10-20%.The addition of prophylactic brain irradiation to limited stage cases has reduced mortality by a factor of nearly 5%. But despite these early good results no breakthrough came later on, and in the last decade or so, we are still facing this plateau. New agents have recently been included in the therapeutic armamentarium, such as gemcitabine, irinotecan, paclitaxel. This fact has allowed many patients to receive a relatively active second line therapy, but the overall survival remains unchanged. Targeted therapies are undergoing some evaluations, but the data are too premature and so far quite discouraging. At the present time there is a urgent need to improve clinical research in this somehow forgotten disease

Published
2006

17. Clinical risk or molecular risk: What matters in low grade gliomas? A study from the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

Author

Franceschi, E., primary, De Biase, D., additional, Paccapelo, A., additional, Reni, M., additional, Mura, A., additional, Tallini, G., additional, Bortolotti, C., additional, Volpin, L., additional, Marucci, G., additional, Cirillo, L., additional, Pession, A., additional, Ghimenton, C., additional, Poggi, R., additional, Bartolini, S., additional, Albini Riccioli, L., additional, Tosoni, A., additional, Degli Esposti, C., additional, Danieli, D., additional, Genestreti, G., additional, and Brandes, A.A., additional

Published
2016
Full Text
View/download PDF

18. First-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced Non Small Cell Lung Cancer. The TORCH randomised trial

Author

Gridelli, C, Ciardiello, F, Gallo, C, Feld, R, Butts, C, Gebbia, V, Maione, P, Morgillo, F, Genestreti, G, Favaretto, A, Leighl, N, Wierzbicki, R, Cinieri, S, Alam, Y, Siena, S, Tortora, Giampaolo, Felletti, R, Riccardi, F, Mancuso, G, Rossi, A, Cantile, F, Tsao, M. S., Saieg, M, da Cunha Santos, G, Piccirillo, Mc, Di Maio, M, Morabito, A, and Perrone, F.

Subjects
NSCLC, Erlotinib, Chemotherapy
Published
2012

29. Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETS): an Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro Il Cancro Del Polmone)

Author

Genestreti, G., primary, Burgio, M.A., additional, Ampollini, L., additional, Sanna, S., additional, Monti, M., additional, Santo, A., additional, Mezzetti, M., additional, Gavelli, G., additional, Verlicchi, A., additional, and Buosi, R., additional

Published
2012
Full Text
View/download PDF

33. Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): Pooled analysis of two randomized trials.

Author

Ardizzoni, A., primary, Boni, L., additional, Tiseo, M., additional, Vincent, A., additional, Passalacqua, R., additional, Camerini, A., additional, Labianca, R., additional, Genestreti, G., additional, Zanelli, F., additional, Ciuffreda, L., additional, Di Costanzo, F., additional, De Marinis, F., additional, Crinò, L., additional, Santo, A., additional, Pazzola, A., additional, Barbieri, F., additional, Zilembo, N., additional, Colantonio, I., additional, Tibaldi, C., additional, and Smit, E. F., additional

Published
2011
Full Text
View/download PDF

35. International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial.

Author

Gridelli, C., primary, Ciardiello, F., additional, Feld, R., additional, Butts, C. A., additional, Gebbia, V., additional, Genestreti, G., additional, Favaretto, A. G., additional, Wierzbicki, R., additional, Gallo, C., additional, and Perrone, F., additional

Published
2010
Full Text
View/download PDF

40. Preliminary results of G versus GViElC: A phase III trial of gemcitabine associated to vindesine or gemcitabine alone in elderly or poor performance patients with advanced non-small cell lung cancer (NSCLC)

Author

Santo, A., primary, Genestreti, G., additional, Terzi, A., additional, Azzoni, P., additional, Caffo, O., additional, Galligioni, E., additional, Cipriani, A., additional, Binato, E., additional, Cartei, G., additional, and Cetto, G., additional

Published
2006
Full Text
View/download PDF

43. Efficacy of Two Different Platinum- or Anthracycline- Containing Chemotherapy Regimens for the Treatment of Small Cell Lung Cancer

Author

Tassinari, D., primary, Genestreti, G., additional, Pasquini, E., additional, Papi, M., additional, Fantini, M., additional, Tamburini, E., additional, Fochessati, F., additional, Poggi, B., additional, Imola, M., additional, Mianulli, A.M., additional, Fattori, P.P., additional, Lazzari-agli, L., additional, Ioli, G., additional, Sartori, S., additional, and Ravaioli, A., additional

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results